Amgen, Sandoz Both Appeal For En Banc Hearing, Amgen Seeks Injunction

Amgen and Sandoz - the two biological drug companies locked in litigation around the biosimilar patent dance and market notification requirements - both appealed to have the full Federal Circuit appeals court hear their case after the initial panel of judges returned a fractured opinion that ruled the patent exchange optional and the market notification only effective after the drug has been licensed. Amgen additionally filed a motion Wednesday (Aug. 26) to block Sandoz's biosimilar product Zarxio from coming to...